Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11848MR)

This product GTTS-WQ11848MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11848MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9244MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ9614MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ1535MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ6535MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ6245MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ14526MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ3468MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ14617MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW